Channels Abrocitinib Achieves Early and Complete/Near-Complete Skin Clearance Plus Itch-Free State in Atopic Dermatitis: Phase 3 Pooled Post Hoc Analysis
Optimizing Abrocitinib Use for Atopic Dermatitis in India: Expert Recommendations for Patient Selection, Dosing, and Long‑Term Remission
Corrigendum to “Effectiveness and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials”
The Importance of Achieving High Treatment Targets in Atopic Dermatitis: A Narrative Review
Incidence of Skin Infections in Patients with Atopic Dermatitis Treated with Topical Medications: A Cohort Study Using Japanese Claims Data
Corticosteroid Phobia in Patients with Atopic Dermatitis: A Narrative Review
Efficacy of Upadacitinib in Patients with Atopic Dermatitis of the Head and Neck Region
Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis)
Review on the Application of Biologic Factors in Atopic Dermatitis and Chronic Spontaneous Urticaria
Do Medication Beliefs Influence Adherence to Topical Therapies in Patients With Atopic Dermatitis?
Topical Corticosteroid Phobia in Childhood Atopic Dermatitis: A Study Using the TOPICOP Score
Mental Health Among Caregivers of Children With Atopic Dermatitis: A Systematic Review With Meta‐Analysis
Duration-Dependent Adverse Events of Systemic Glucocorticosteroids in Atopic Dermatitis: A Nationwide Claims Cohort Study
Evolving Research Hotspots and Emerging Trends in Atopic Dermatitis and Inflammatory Bowel Disease: A Bibliometric Analysis
Achieving Canadian Treat-to-Target Criteria in Moderate-to-Severe Atopic Dermatitis: A Retrospective Analysis of Outcomes from Real-World Canadian Practice
Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would be Eligible for Treatment Based on the South Korean Reimbursement Criteria
Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)
A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence
Biochemical Mechanisms Mediating the Immunomodulatory and Anti-Atopic Dermatitis Effects of GammaQ in a DNCB-Induced BALB/c Mouse Model
Patient‐Centred Care in Atopic Dermatitis: Digital Communication, Misinformation, and Global Perspectives From the Pacecad Sessions (Isad Rajka Symposium, Melbourne 2025)
Prevalence and Burden of Somatic Symptom Disorder in Atopic Dermatitis and Chronic Pruritus—The Persistent Somatic Symptoms Across Diseases: Pruritus (SOMA.PRU) Study
REVEAL AD ‐ Prevalence of Moderate and Severe Atopic Dermatitis in Ireland: A Cross‐ Sectional, Real World Study of a Secondary Care Population
Letter to the Editor Regarding “Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis”
A Response to: “Letter to the Editor Regarding ‘Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis’”
Clinically Meaningful Improvements in Quality of Life, Including Sleep, With Two‐Week and Monthly Dosed Rademikibart: A Phase 2 Randomized Trial in Adults With Moderate‐to‐Severe Atopic Dermatitis
